US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

49.19

-0.2900-0.59%

Post-market: 49.190.00000.00%19:30 EDT

Volume:322.54K

Turnover:15.89M

Market Cap:15.04B

PE:22.06

High:49.58

Open:49.49

Low:49.03

Close:49.48

52wk High:55.49

52wk Low:45.77

Shares:305.78M

Float Shares:305.78M

Volume Ratio:0.65

T/O Rate:0.11%

Dividend:2.11

Dividend Rate:4.29%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.61

PE(LYR):19.95

Loading ...

Overview Company News Filings

Calendar of U.S. Earnings Expected in the Week Ahead

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Press Release: Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Earning Preview: Emera Inc. this quarter’s revenue is expected to increase by 35.49%, and institutional views are Neutral

OS Therapies Gains EMA Rolling Review for OST-HER2

Press Release: Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Emera Inc : Barclays Initiates Coverage With Equal-Weight Rating and Target Price $53

THOMSON REUTERS

Emera initiated with an Equal Weight at Barclays

Analysts Have Conflicting Sentiments on These Utilities Companies: Emera (EMA), Origin Energy Limited (OtherOGFGF) and Clearway Energy (CWEN)

A Look At Arrowhead Pharmaceuticals (ARWR) Valuation After EMA CHMP Backs REDEMPLO For FCS

Simply Wall St.

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies

MT Newswires Live

PYC Wins EMA Orphan Status for RP11 Gene Therapy Candidate VP-001

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/EMA/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":49.19,"timestamp":1789156800000,"preClose":49.48,"halted":0,"volume":322535,"hourTrading":{"tag":"盘后","latestPrice":49.19,"preClose":49.19,"latestTime":"19:30 EDT","volume":114920,"amount":5650342.26916,"timestamp":1789169408200,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.005860953920776055,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Market Closed","change":-0.29,"latestTime":"09-11 16:00:00 EDT","open":49.49,"high":49.58,"low":49.03,"amount":15887316.78782,"amplitude":0.011116,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":49.48,"dividendRate":0.04287,"postHourTrading":{"tag":"盘后","latestPrice":49.19,"preClose":49.19,"latestTime":"19:30 EDT","volume":114920,"amount":5650342.26916,"timestamp":1789169408200,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6549588303916867,"impliedVol":0.3093,"impliedVolPercentile":0.8884},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":0.6549588303916867,"shares":305783111,"dividePrice":2.108663,"high":49.58,"amplitude":0.011116,"preClose":49.48,"low":49.03,"week52Low":45.77,"pbRate":"1.61","psRate":"2.33","week52High":55.49,"institutionHeld":0,"latestPrice":49.19,"eps":2.229761,"divideRate":0.042868,"volume":322535,"delay":0,"ttmEps":2.229761,"open":49.49,"prevYearClose":49.24,"prevWeekClose":50.35,"prevMonthClose":50.09,"prevQuarterClose":53.02,"fiveDayClose":50.3,"twentyDayClose":51.34,"sixtyDayClose":52.55,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-09-11","current":22.06066,"percent":0.489097,"low":16.637027,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"high":22.07626,"avg":19.825742,"sd":1.478156,"marketCap":15223834714.33},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-09-04","current":20.473108,"twenty":17.659944,"median":20.257815,"eighty":21.043803,"marketCap":15442660903.12},{"date":"2026-09-11","current":20.227938,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"marketCap":15223834714.33}],"updateTime":1789255162040},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633434311","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2633434311","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633434311?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:00","pubTimestamp":1778234400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Alpha Metal Res                                  1Q      (.36)   7:30 AM. ·Plains All Am                                    1Q       .37    7:30 AM. ·Plains GP A                                     1Q       .46    7:30 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIP","EMBJ","APC","CINT","CHRS","ENTA","CDRE","BATRK","AU","DCH","CERT","APEI","BCSF","BATRA","ABCL","AMTM","CEG","BLNK","FIGR","EXPI","FIS","ASTS","AMCX","ACH","ENB","CNTY","DCGO","B","ESNT","CEVA","BTAI","TM","CGBD","FHTX","BCAX","ACM","AMR","CBLL","BAM","DDD","ALXO","CLMT","CRCL","EMA","CVRX","AQN","DCBO","CLLS","CLSK","ASRT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633552172","title":"CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2633552172","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633552172?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:05","pubTimestamp":1778184300,"startTime":"0","endTime":"0","summary":"Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGA","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290541/0/en/CAMP4-Reports-First-Quarter-2026-Financial-Results-and-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633817649","title":"BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633817649","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633817649?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:01","pubTimestamp":1778184060,"startTime":"0","endTime":"0","summary":"$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby net product revenue, with strong prescribing growth and patient persistence driving continued commercial mom","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290504/0/en/BridgeBio-Reports-First-Quarter-2026-Financial-Results-and-Corporate-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","EMA","MAA","BK4588","BK4081","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145418","title":"Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145418","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145418?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:05","pubTimestamp":1778151900,"startTime":"0","endTime":"0","summary":"1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M  40% Confirmed Objective Response Rate in Metastatic Serous Endometrial","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289839/0/en/Iovance-Biotherapeutics-Highlights-Positive-First-Quarter-2026-Results-Business-Achievements-and-Corporate-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052756011.USD","BK4131","BK4108","LU0320765489.SGD","BK4509","IOVA","LU0269904917.USD","LU0359202008.SGD","LU0149725797.USD","IE00BJJMRY28.SGD","BK4531","IE00B12V2V27.USD","LU0456842615.SGD","IE00BJJMRX11.SGD","LU1585245621.USD","BK4139","TME","LU0070302665.USD","LU2237438978.USD","BK4535","BK4081","BK4585","IND","LU0359201612.USD","LU1430594728.SGD","BK4534","LU0061475181.USD","TIL","IE00B7SZLL34.SGD","BK4563","BK4552","LU1074936037.SGD","LU1162221912.USD","LU1023057109.AUD","IE0002270589.USD","IE00B19Z3581.USD","LU0828238088.HKD","BK4550","EMA","IE0004445015.USD","LU0128525689.USD","LU1894683264.USD","UPS","LU2133065610.SGD","SG9999011746.SGD","01698","LU1894683348.USD","MAA","LU0310800965.SGD","BK4571"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633199391","title":"Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2633199391","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633199391?lang=en_us&edition=fundamental","pubTime":"2026-05-07 16:57","pubTimestamp":1778144220,"startTime":"0","endTime":"0","summary":"Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON)FDA Breakthrough Therapy and EMA PRIME desi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289657/0/en/Oculis-Announces-Agreement-with-FDA-on-a-Special-Protocol-Assessment-SPA-for-Optic-Neuritis-Registrational-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0098860793.USD","BK4007","LU1074936037.SGD","LU1363072403.SGD","LU1854103824.USD","BK4127","LU0320765646.SGD","IE00BZ199S13.USD","LU2357305700.SGD","BK4516","OCS","LU0795875086.SGD","LABU","LU1861215975.USD","EMA","LU1791710582.SGD","LU0795875169.SGD","LU1244550221.USD","LU0106831901.USD","LU0234570918.USD","LU1989772923.USD","LU2360107325.USD","LU0158827781.USD","ON","IE00BZ1G4Q59.USD","BK4605","LU1978683503.SGD","LU1244550494.USD","LU1861220033.SGD","LU1989772840.SGD","LU1548497426.USD","LU2089283258.USD","BK4588","LU0006306889.USD","LU1162221912.USD","LU1861214812.USD","IE00BFMHRM44.USD","LU2133065610.SGD","LU0267386448.USD","LU0971096721.USD","LU0557290698.USD","IE00BKVL7J92.USD","LU2271345857.HKD","LU0912757837.SGD","LU1244550577.SGD","LU1720051017.SGD","LU0158827948.USD","LU2264538146.SGD","LU0124384867.USD","LU0882574139.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633591711","title":"Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2633591711","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633591711?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:02","pubTimestamp":1778097720,"startTime":"0","endTime":"0","summary":"Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3289308/0/en/Revolution-Medicines-Reports-First-Quarter-2026-Financial-Results-and-Update-on-Corporate-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","BK4139","LU1978683503.SGD","BK4211","LU1861220033.SGD","EMA","LU2357305700.SGD","LU2360107325.USD","BK4512","LU1861215975.USD","LU2298322129.HKD","IE00BFMHRM44.USD","BK4081","CRC","LU1720051108.HKD","LU1854103824.USD","BK4605","BK4097","LU0348723411.USD","IE00BD6J9T35.USD","BK4213","ODD","PRGS","LU0724618433.USD","IE00BZ199S13.USD","PFS","RVMD","BK4588","BK4585","BK4141","LU1861214812.USD","LU0456854461.SGD","LU1720051017.SGD","BK4183","LU1548497426.USD","LU1854104046.USD","ON","IE0009354923.USD","BMS","BK4195","LU1861219969.SGD","LU0124384867.USD","LU0266512127.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633651649","title":"Press Release: Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633651649","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633651649?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:10","pubTimestamp":1777925400,"startTime":"0","endTime":"0","summary":"Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI ; majority of the approximately 200 patients started on IBTROZI in the first quarter of 2026 were TKI-nave, highlighting continued momentum in the first-line setting. Presented newly updated clinical data demonstrating IBTROZI's impressive durability of response and progression-free survival in TKI-nave and TKI-pretreated patients with advanced ROS1-positive  non-small cell lung cancer  at AACR 2026. Announced acquisition of Japan rights to safusidenib from Daiichi Sankyo, enabling global development and commercialization of promising investigational medicine. Strong balance sheet with cash, cash equivalents, and marketable securities of $533.7 million as of March 31, 2026. NEW YORK, May 4, 2026 /PRNewswire/ -- Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the first quarter ended March 31, 2026, an","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","R","CNS","BK4007","MAA","DDC","BK4585","BK4022","BK4212","EMA","BK4232","NUVB","BK4215","BK4135","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632495887","title":"BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2632495887","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632495887?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:30","pubTimestamp":1777894200,"startTime":"0","endTime":"0","summary":"PALO ALTO, Calif., May  04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3286590/0/en/BridgeBio-to-Present-New-Acoramidis-Data-on-Disease-Progression-Biomarkers-and-Clinical-Outcomes-at-ESC-Heart-Failure-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632618574","title":"Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2632618574","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632618574?lang=en_us&edition=fundamental","pubTime":"2026-05-01 16:00","pubTimestamp":1777622400,"startTime":"0","endTime":"0","summary":"Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to be presented by Baruch Kupperman","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/01/3285711/0/en/Oculis-to-Present-at-Upcoming-Association-for-Research-in-Vision-and-Ophthalmology-ARVO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4512","LU1854104046.USD","LU2360107325.USD","LU2298322129.HKD","OCS","BK4141","IE00BZ199S13.USD","LU1861220033.SGD","LU2357305700.SGD","LU0124384867.USD","LU0348723411.USD","EMA","BK4585","LU1861214812.USD","LU1720051017.SGD","LU0724618433.USD","ON","LU1978683503.SGD","BK4605","IE00BFMHRM44.USD","BK4007","LU1861219969.SGD","BK4588","IE00BD6J9T35.USD","LU1854103824.USD","LU1861215975.USD","LU1548497426.USD","LU1720051108.HKD","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632572618","title":"Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2632572618","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632572618?lang=en_us&edition=fundamental","pubTime":"2026-05-01 16:00","pubTimestamp":1777622400,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland, May  01, 2026 (GLOBE NEWSWIRE) -- Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/01/3285712/0/en/Oculis-to-Present-at-Upcoming-Association-for-Research-in-Vision-and-Ophthalmology-ARVO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861214812.USD","BK4007","LU1861215975.USD","LU0124384867.USD","IE00BD6J9T35.USD","LU1720051017.SGD","LU2360107325.USD","LU2298322129.HKD","BK4141","LU0348723411.USD","BK4605","OCS","LU1861219969.SGD","ON","IE00BFMHRM44.USD","LU1978683503.SGD","EMA","LU2357305700.SGD","LU1854103824.USD","LU1548497426.USD","LU1854104046.USD","BK4585","IE00BZ199S13.USD","LU0724618433.USD","BK4512","LU1861220033.SGD","BK4588","LU1720051108.HKD","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111536925","title":"Earning Preview: Emera Inc. this quarter’s revenue is expected to increase by 35.49%, and institutional views are Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=1111536925","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111536925?lang=en_us&edition=fundamental","pubTime":"2026-05-01 09:23","pubTimestamp":1777598598,"startTime":"0","endTime":"0","summary":"Abstract Emera Inc. is scheduled to report quarterly results on May 8, 2026 Pre-Market; this preview summarizes the latest actuals and current-quarter forecasts on revenue, profitability, and EPS,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Emera Inc. this quarter’s revenue is expected to increase by 35.49%, and institutional views are Neutral","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632664219","title":"OS Therapies Gains EMA Rolling Review for OST-HER2","url":"https://stock-news.laohu8.com/highlight/detail?id=2632664219","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632664219?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:18","pubTimestamp":1777583885,"startTime":"0","endTime":"0","summary":"OS Therapies Incorporated ( ($OSTX) ) has issued an announcement. On April 30, 2026, OS Therapies announced that the European Medicines Agency has ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-gains-ema-rolling-review-for-ost-her2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-gains-ema-rolling-review-for-ost-her2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","OSTX","BK4139","BK4148","EMA","OST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631902435","title":"Press Release: Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution","url":"https://stock-news.laohu8.com/highlight/detail?id=2631902435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631902435?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:00","pubTimestamp":1777460400,"startTime":"0","endTime":"0","summary":"For an accessible version of this Press Release, please visit www.tevapharm.com. -- Q1 2026 revenues of $4.0 billion increased by 2% in U.S. dollars. year-over-year , and decreased by 3% in local currency terms .Excluding the Japan business venture  results, revenues decreased by. 1% in LC. These strong first quarter results were driven by our. innovative portfolio growth and disciplined execution, even with lower. due to increased generic competition in the U.S.-- Key Innovative brands continued to drive growth and provide value for. patients, while transforming Teva's portfolio mix and financial profile:. -- AUSTEDO continued to show strong growth, with global revenues. of $578 million, growing 41% YoY in LC.-- AJOVY global revenues of $196 million, increased by 35% YoY in. -- UZEDY revenues of $63 million, increased by 62% YoY in LC.Fastest growing long-acting injectable 1 has nearly doubled. -- Collectively these brands' revenues grew by 41% YoY in LC.-- Generics revenues are lower","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4116","BK4120","BK4007","LC","CD","LU1861220207.SGD","03160","LU2324357040.USD","R","BK4022","BK4596","BK4232","BK4585","BK4566","TM","BK4215","BK4584","BK4559","LU1861217088.USD","MAA","BK4604","BK4557","EMA","BK4099","LU1983299246.USD","BK4555","BK4081","BK4588","LU2360107671.USD","BK4023","BK4166","BV","TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630209377","title":"Emera Inc : Barclays Initiates Coverage With Equal-Weight  Rating  and Target Price $53","url":"https://stock-news.laohu8.com/highlight/detail?id=2630209377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630209377?lang=en_us&edition=fundamental","pubTime":"2026-04-28 18:17","pubTimestamp":1777371445,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0JH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630377020","title":"Emera initiated with an Equal Weight at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2630377020","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630377020?lang=en_us&edition=fundamental","pubTime":"2026-04-28 18:16","pubTimestamp":1777371399,"startTime":"0","endTime":"0","summary":"Barclays initiated coverage of Emera (EMA) with an Equal Weight rating and $53 price target The firm believes the company’s premium Florida regulat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emera-initiated-with-an-equal-weight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emera-initiated-with-an-equal-weight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630225347","title":"Analysts Have Conflicting Sentiments on These Utilities Companies: Emera (EMA), Origin Energy Limited (OtherOGFGF) and Clearway Energy (CWEN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2630225347","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630225347?lang=en_us&edition=fundamental","pubTime":"2026-04-28 09:50","pubTimestamp":1777341028,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Utilities sector with new ratings on Emera (EMA), Origin Energy Limited (OGFGF) and Clearway Energy (CW...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-utilities-companies-emera-ema-origin-energy-limited-otherogfgf-and-clearway-energy-cwen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-utilities-companies-emera-ema-origin-energy-limited-otherogfgf-and-clearway-energy-cwen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BZ18W456.USD","BK4081","OGFGF","BK4133","IE00BMQBXF63.USD","EMA","BK4105","CWEN","IE00BZ18W340.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630343317","title":"A Look At Arrowhead Pharmaceuticals (ARWR) Valuation After EMA CHMP Backs REDEMPLO For FCS","url":"https://stock-news.laohu8.com/highlight/detail?id=2630343317","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630343317?lang=en_us&edition=fundamental","pubTime":"2026-04-28 05:06","pubTimestamp":1777324015,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals (ARWR) is back in focus after the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion on REDEMPLO, its siRNA therapy for familial chylomicronemia syndrome in Europe.\nSee our latest analysis for Arrowhead Pharmaceuticals.\nThe CHMP opinion comes after a powerful run in the shares, with a 1 month share price return of 27.92% and a 7 day gain of 6.73%. The 1 year total shareholder return is very large, suggesting momentum has been building...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/a-look-at-arrowhead-pharmaceuticals-arwr-valuation-after-ema","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/a-look-at-arrowhead-pharmaceuticals-arwr-valuation-after-ema","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4585","DCF","EMA","BK4139","ARWR","CHMP","BK4081","BK4087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630435456","title":"Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2630435456","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630435456?lang=en_us&edition=fundamental","pubTime":"2026-04-27 13:15","pubTimestamp":1777266900,"startTime":"0","endTime":"0","summary":"Significant improvements as early as Week 1,favorable safety profileand no liversafetyconcerns in REMIX 1 & 2studies of highly selective, oral BTKi1Rhapsidorecommended in2026 InternationalUrticaria Gu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281278/0/en/Novartis-Rhapsido-receives-European-Commission-approval-as-first-oral-targeted-treatment-for-chronic-spontaneous-urticaria.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","EC","BK4081","BK4087","BK4201","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630333203","title":"Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2630333203","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630333203?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:14","pubTimestamp":1777248895,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  is unlikely to seek regulatory approval for Scenesse in vitiligo until the Phase 3 CUV105 and CUV107 clinical trials are completed, according to a Friday Jefferies note.The company said on Friday that the European Medicines Agency  has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a \"totality of evidence\" regulatory approach.Jefferies said that the EMA's decision is a positive for the company because of the high unmet medical need for Vitiligo treatment.The investment firm has pushed back its revenue expectations from Scenesse in vitiligo, which is now expected to begin in the second half of fiscal 2029 rather than fiscal 2028.Jefferies kept a buy rating on Clinuvel and cut its price target to AU$39.20 from AU$40.50.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7129","BK4081","BK7508","EMA.AU","EMA","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630337810","title":"PYC Wins EMA Orphan Status for RP11 Gene Therapy Candidate VP-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2630337810","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630337810?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:07","pubTimestamp":1777248433,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited ( ($AU:PYC) ) has provided an announcement. PYC Therapeutics has secured Orphan Drug Designation from the European Medicin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pyc-wins-ema-orphan-status-for-rp11-gene-therapy-candidate-vp-001?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pyc-wins-ema-orphan-status-for-rp11-gene-therapy-candidate-vp-001?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}